Home Alzheimer’s Disease

Alzheimer’s Disease

Study Supports Increased Referrals of Genetic Testing in African American Women

A study, published in the Journal of the National Cancer Institute, identified genes that predispose the African American population to breast cancer.1 Importantly, the study also...

Elizabeth Plimack, MD, MS, Discusses Subsequent Therapy in Advanced RCC

Elizabeth Plimack, MD, MS, of the Fox Chase Cancer Center in Philadelphia, discussed the role of subsequent immunotherapy when analyzing the primary endpoint of...

Meletios A. Dimopoulos, MD, on the Phase III BOSTON Study in Multiple Myeloma

Meletios A. Dimopoulos, MD, discussed the phase III Boston study presented at the 2020 ASCO Virtual Scientific Program examining a new combination therapy to...

Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Results of the Phase III ASPEN Trial

Results from the randomized phase III ASPEN trial, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting, indicated that zanubrutinib...

Clinical Improvement Found After Administration of Acalabrutinib for Patients with COVID-19

Clinical outcomes improved and reduced markers of inflammation were seen after administration of acalabrutinib (Calquence) for patients with severe coronavirus disease 2019 (COVID-19), according...

Belantamab Mafodotin Triplet Yields Promising Clinical Benefit in Relapsed/Refractory Multiple Myeloma

The combination use of belantamab mafodotin plus bortezomib (Velcade) and dexamethasone (B-Vd) induced high clinical benefit rates and a tolerable safety profile in patients...

Caron A. Jacobson, MD, on the Interim Phase II ZUMA-5 Study Safety and Efficacy Findings

Results from the interim analysis of the phase II ZUMA-5 study, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program,...

JNJ-4528 Continues to Show Durable Responses in Relapsed/Refractory Multiple Myeloma

JNJ-4528, a chimeric antigen receptor (CAR) T-cell therapy, continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according...

Niraparib-Bevacizumab Combo Improves Clinical Outcomes in Recurrent Ovarian Cancer

The combination use of niraparib (Zejula) plus bevacizumab (Avastin) significantly improved clinical outcomes, compared with niraparib alone, in patients with recurrent ovarian cancer, according...

Quiz: When to Use Endoscopy for Acute Upper Gastrointestinal Bleeding

1. In patients with upper gastrointestinal bleeding who are predicted to be at high risk for further bleeding or death, when should endoscopy be...

ASCO Expert Discusses the Use of Autologous Transplantation in Relapsed DLBCL

In an interview with CancerNetwork®, Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, discussed the use of autologous stem cell transplant in...

Ide-cel Appears Active in Almost Three-Fourths of Heavily Pretreated Patients with Myeloma

Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeting CAR T-cell therapy, yielded a response in73% of patients with heavily pretreated relapsed/refractory multiple myeloma, according to topline...

Most Read

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...